ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Clinical Trials: NCI Issues Clinical Alert On Chemo For Cervical Cancer

February 26, 1999

Low-Dose Warfarin Prevents Blood Clots, NIH Study Finds

February 28, 2003

Changes Put Pharma In Control Of Trials Traditionally Conducted By Academics.

March 26, 2010

Wyden Compared Taxol To AZT; But Experts Note Lack Of Patent

August 9, 1991

NCI considers allowing some centers to opt out of site visits.

March 19, 2004

In Brief: NCI To Push “Cancer Prevention Awareness” This Month; Three RFPs Delayed For Changes

February 17, 1984